Celldex Posts Positive 3-Year Survival Data from Phase 2 Rindopepimut Program

Celldex Therapeutics, Inc. CLDX announced today the presentation of three-year survival data from the Phase 2 rindopepimut clinical program in EGFRvIII-positive glioblastoma—a more aggressive form of glioblastoma typically associated with reduced long-term survival in comparison to the glioblastoma population as a whole. Across three Phase 2 studies of rindopepimut, survival data remains consistent and suggests a substantial and continuing survival benefit in comparison to independent control datasets (see chart below) at the median and at three years. In the multi-center Phase 2 ACT III study, the median overall survival is 24.6 months from diagnosis (21.8 months from study entry) and overall survival is 26% at three years. In the Phase 2 ACT II study, the median overall survival is 24.4 months from diagnosis (20.5 months from study entry) and overall survival is 23% at three years. In the Phase 2 ACTIVATE study, the median overall survival is 24.6 months from diagnosis (20.4 months from study entry) and overall survival is 33% at three years. Rindopepimut Overall Survival (OS) Across Three Phase 2 Studies in EGFRvIII-Positive Glioblastoma vs Independent Control Datasets Rindopepimut Phase 2 Studies (all data from study entry)       Median     OS 3 years (months) ACT III (n=65)     21.8     26% ACT II (n=22)     20.5     23% ACTIVATE (n=18)     20.4     33% Independent Control Datasets (all data from study entry) MD Anderson EGFRvIII-positive patients matched^1 to ACTIVATE patient population (n=17)     12.2^2     6% (contemporary with ACTIVATE) Radiation Therapy Oncology Group (RTOG) 0525 study - all EGFRvIII-positive patients (n=142)     15.1     18% (contemporary with ACT III) RTOG 0525 study - all EGFRvIII-positive patients treated with standard dose temozolomide (n=62)     14.2     7% (contemporary with ACT III) RTOG 0525 study - EGFRvIII-positive patients matched^1 to ACT III/IV patient population (n=29)     16     13% (contemporary with ACT III) ^1Controls are closely matched to rindopepimut patient criteria including gross total resection of patient tumor and ~3 months without disease progression at time of study entry; ^2In order to provide comparable timeframes across datasets, data have been estimated assuming study entry at three months from diagnosis.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!